FindTrial
Sign In

Clinical significance of serological markers combined with immunological markers in the prognosis of colorectal cancer

Clinical significance of serological markers combined with immunological markers in the prognosis of colorectal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17013489
Enrollment
Unknown
Registered
2017-11-22
Start date
2018-01-01
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Case series:Nil

Sponsors

Cangzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) patients with colorectal cancer and underwent primary radical resection; (2) patients who provided a signed informed consent for the collection of pathological specimens and preservation of pathological tissues, and (3) patients with stage I or II colorectal cancer diagnosed according to the Seventh Edition of the American Joint Committee on Cancer (AJCC) tumor staging guidelines.

Exclusion criteria

Exclusion criteria: (1) patients who received chemotherapy treatment prior to admission to our hospital, and (2) patients who received radical surgery were combined with other tumors.

Design outcomes

Primary

MeasureTime frame
tumor tissue Pgp1;Serum CEA;—

Countries

China

Contacts

Public ContactZunyi Wang
1332744769@qq.com+86 0317-2075979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026